Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse
October 18th 2024Panelists discuss how recent advancements in the treatment of newly diagnosed multiple myeloma (MM) and early relapse, particularly the role of chimeric antigen receptor T-cell therapy, are reshaping therapeutic strategies and improving patient outcomes.
Advancements in the Management of Gynecological Cancers: ESMO 2024
September 30th 2024In this OncLive Peer Exchange series, a panel of experts discusses the latest advancements in the management of gynecological cancers, highlighting updates from ESMO 2024, including treatment paradigms for advanced ovarian, cervical, and endometrial cancers, biomarker testing strategies, and emerging therapies such as antibody-drug conjugates.
ESMO 2024: Targeting the Treatment Challenges of Small Cell Lung Cancer
September 30th 2024Panelists discuss how recent clinical trials and innovative therapies are reshaping the treatment landscape for small cell lung cancer, emphasizing the importance of personalized approaches and multidisciplinary strategies to improve patient outcomes.
EHA 2024: Updates in the Treatment of CLL
June 27th 2024Catherine C. Coombs, MD, Matthew S. Davids, MD, MMSc; Richardo D. Parrondo, MD; Nicole Lamanna, MD, and Alexey Danilov, MD, PhD, examine treatment approaches for newly diagnosed chronic lymphocytic leukemia (CLL), including BTK inhibitor therapy, management of adverse events, and strategies for relapsed/refractory CLL.
Evolving Treatments of Metastatic CRC: Insights from ASCO 2024
June 25th 2024John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.
Lower-Risk Myelodysplastic Syndromes (LR-MDS): Highlights from EHA 2024
June 24th 2024Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.
ASCO 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma
June 21st 2024A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.
Targeting NSCLC with Precision: Evaluation of the Emerging Role of Antibody-Drug Conjugates
June 21st 2024Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.
Utilizing Different Mechanisms of Action for Treatment of Chronic Graft-Versus-Host Disease
January 9th 2024Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.